[Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy]. 1990

N Takifuji, and M Fukuoka, and S Negoro, and M Takada, and Y Kusunoki, and K Matsui, and N Masuda, and S Ryu, and N Sakai, and K Kubota
Dept. of Internal Medicine, Osaka Prefectural Habikino Hospital.

One-hundred and ninety-nine patients who had an inoperable stage III or IV non-small cell lung cancer (NSCLC) and collected were analyzed on the basis of factors affecting survival duration and response to chemotherapy. These patients were registered into a prospective randomized trial conducted from May of 1986 to April of 1988, and received either cisplatin and vindesine, cisplatin, vindesine and mitomycin C, or cisplatin and etoposide alternating with vindesine and mitomycin C. In the univariate analysis, sex, ECOG's performance status (PS), weight loss within previous 6 months, clinical stage, serum albumin value, serum lactate dehydrogenase level and hemoglobin (Hb) level were considered to be significant factors for survival (p less than 0.05). In the multivariable analysis using Cox's proportional model, clinical stage, PS, sex, weight loss and Hb level were proven to be significant variables for survival in the order of importance. When the response to chemotherapy was included in a conditional multivariable analysis, it was strongly associated with survival duration. A multivariable analysis of response using the logistic regression method demonstrated that female sex, cisplatin, vindesine and mitomycin combination regimen, squamous cell type, and no weight loss were significantly predictive of response outcome. These results are useful when comparing the response data and survival of completed studies and designing future trials in advanced NSCLC.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D012044 Regression Analysis Procedures for finding the mathematical function which best describes the relationship between a dependent variable and one or more independent variables. In linear regression (see LINEAR MODELS) the relationship is constrained to be a straight line and LEAST-SQUARES ANALYSIS is used to determine the best fit. In logistic regression (see LOGISTIC MODELS) the dependent variable is qualitative rather than continuously variable and LIKELIHOOD FUNCTIONS are used to find the best relationship. In multiple regression, the dependent variable is considered to depend on more than a single independent variable. Regression Diagnostics,Statistical Regression,Analysis, Regression,Analyses, Regression,Diagnostics, Regression,Regression Analyses,Regression, Statistical,Regressions, Statistical,Statistical Regressions
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum

Related Publications

N Takifuji, and M Fukuoka, and S Negoro, and M Takada, and Y Kusunoki, and K Matsui, and N Masuda, and S Ryu, and N Sakai, and K Kubota
January 2009, Oncology,
N Takifuji, and M Fukuoka, and S Negoro, and M Takada, and Y Kusunoki, and K Matsui, and N Masuda, and S Ryu, and N Sakai, and K Kubota
September 2023, Cancers,
N Takifuji, and M Fukuoka, and S Negoro, and M Takada, and Y Kusunoki, and K Matsui, and N Masuda, and S Ryu, and N Sakai, and K Kubota
March 2015, Open access Macedonian journal of medical sciences,
N Takifuji, and M Fukuoka, and S Negoro, and M Takada, and Y Kusunoki, and K Matsui, and N Masuda, and S Ryu, and N Sakai, and K Kubota
September 2004, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
N Takifuji, and M Fukuoka, and S Negoro, and M Takada, and Y Kusunoki, and K Matsui, and N Masuda, and S Ryu, and N Sakai, and K Kubota
January 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
N Takifuji, and M Fukuoka, and S Negoro, and M Takada, and Y Kusunoki, and K Matsui, and N Masuda, and S Ryu, and N Sakai, and K Kubota
November 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
N Takifuji, and M Fukuoka, and S Negoro, and M Takada, and Y Kusunoki, and K Matsui, and N Masuda, and S Ryu, and N Sakai, and K Kubota
May 2016, Annals of translational medicine,
N Takifuji, and M Fukuoka, and S Negoro, and M Takada, and Y Kusunoki, and K Matsui, and N Masuda, and S Ryu, and N Sakai, and K Kubota
January 1992, Cancer chemotherapy and pharmacology,
N Takifuji, and M Fukuoka, and S Negoro, and M Takada, and Y Kusunoki, and K Matsui, and N Masuda, and S Ryu, and N Sakai, and K Kubota
July 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
N Takifuji, and M Fukuoka, and S Negoro, and M Takada, and Y Kusunoki, and K Matsui, and N Masuda, and S Ryu, and N Sakai, and K Kubota
February 2016, Translational oncology,
Copied contents to your clipboard!